Ian Campbell

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi request reprint No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    Cancer Lett 240:195-7. 2006
  2. pmc A rational approach to cancer therapy
    Kylie L Gorringe
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    Genome Biol 9:306. 2008
  3. pmc The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women
    Karen G Montgomery
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Centre, St, Andrews Place, East Melbourne, Victoria, Australia
    Breast Cancer Res 7:R353-6. 2005
  4. pmc The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: a case-control study
    Karen G Montgomery
    Victorian Breast Cancer Research Consortium, Cancer Genetics Laboratory, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
    Breast Cancer Res 6:R390-4. 2004
  5. pmc Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer
    Sally J Davis
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Cancer 11:173. 2011
  6. pmc A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer
    Ella Thompson
    Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1 A Beckett St, Melbourne, Victoria 8006, Australia
    BMC Cancer 5:43. 2005
  7. doi request reprint Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution
    Ian Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 69:6765-8; discussion 6769. 2009
  8. ncbi request reprint Genetic and epigenetic analysis of the putative tumor suppressor km23 in primary ovarian, breast, and colorectal cancers
    Ian G Campbell
    Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, 8006, Australia
    Clin Cancer Res 12:3713-5. 2006
  9. ncbi request reprint Mutation of the PIK3CA gene in ovarian and breast cancer
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer Res 64:7678-81. 2004
  10. pmc No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer
    Ian G Campbell
    Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Victoria, Australia
    Breast Cancer Res 6:R366-71. 2004

Collaborators

Detail Information

Publications47

  1. ncbi request reprint No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    Cancer Lett 240:195-7. 2006
    ..04, 95% CI 0.67-1.60) or ovarian cancer (OR 0.86, 95% CI 0.53-1.37). This study has found no evidence that the GG genotype of the MDM2 SNP309 polymorphism is associated with early onset or familial breast cancer or with ovarian cancer...
  2. pmc A rational approach to cancer therapy
    Kylie L Gorringe
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    Genome Biol 9:306. 2008
  3. pmc The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women
    Karen G Montgomery
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Centre, St, Andrews Place, East Melbourne, Victoria, Australia
    Breast Cancer Res 7:R353-6. 2005
    ..It contains a glutamine repeat (CAG/CAA) polymorphism at its carboxyl-terminal region that may alter the transcriptional activation of the receptor and affect susceptibility to breast cancer through altered sensitivity to hormones...
  4. pmc The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: a case-control study
    Karen G Montgomery
    Victorian Breast Cancer Research Consortium, Cancer Genetics Laboratory, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
    Breast Cancer Res 6:R390-4. 2004
    ....
  5. pmc Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer
    Sally J Davis
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Cancer 11:173. 2011
    ..MAP2K4 is a putative tumor and metastasis suppressor gene frequently found to be deleted in various cancer types. We aimed to conduct a comprehensive analysis of this gene to assess its involvement in ovarian cancer...
  6. pmc A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer
    Ella Thompson
    Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1 A Beckett St, Melbourne, Victoria 8006, Australia
    BMC Cancer 5:43. 2005
    ..FANCA is also a potential breast and ovarian cancer susceptibility gene. A novel allele was identified which has a tandem duplication of a 13 base pair sequence in the promoter region...
  7. doi request reprint Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution
    Ian Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 69:6765-8; discussion 6769. 2009
    ..We conclude that reported frequent clonal somatic mutations in CAFs are likely to be artefacts and are not the biological basis of the cancer promoting attributes of CAFs. [corrected]..
  8. ncbi request reprint Genetic and epigenetic analysis of the putative tumor suppressor km23 in primary ovarian, breast, and colorectal cancers
    Ian G Campbell
    Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, 8006, Australia
    Clin Cancer Res 12:3713-5. 2006
    ..If verified, this would elevate mutation of km23 as the single most frequent somatic event in ovarian cancer...
  9. ncbi request reprint Mutation of the PIK3CA gene in ovarian and breast cancer
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer Res 64:7678-81. 2004
    ..5% of all ovarian cancers and 45% of the endometrioid and clear cell subtypes. Our study is the first direct evidence that PIK3CA is an oncogene in ovarian cancer and greatly extends recent findings in breast cancer...
  10. pmc No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer
    Ian G Campbell
    Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Victoria, Australia
    Breast Cancer Res 6:R366-71. 2004
    ..We hypothesized that germline mutations in EP300 may account for some breast cancer families that include cases of gastric, pancreatic and/or colorectal cancer...
  11. ncbi request reprint Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer
    Simon W Baxter
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Cancer Epidemiol Biomarkers Prev 11:211-4. 2002
  12. ncbi request reprint Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers
    Louise H Williams
    Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Clin Cancer Res 12:6967-72. 2006
    ..The aim of this study was to determine if somatic mutation and/or epigenetic modification play a role in development of sporadic breast, colon, or ovarian cancers...
  13. ncbi request reprint Breast cancer risk and the BRCA1 interacting protein CTIP
    Kylie L Gorringe
    VBCRC Cancer Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Breast Cancer Res Treat 112:351-2. 2008
    ..No coding variants were detected in CTIP, therefore, it is unlikely to be involved in breast cancer risk...
  14. doi request reprint Genetic changes in tumour microenvironments
    Ian Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Pathol 223:450-8. 2011
    ..It is now clear that clonal somatic mutations are not the biological basis of the cancer-promoting attributes of carcinoma-associated fibroblasts...
  15. ncbi request reprint The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years
    Karen G Montgomery
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Cancer Epidemiol Biomarkers Prev 12:1109-11. 2003
    ..3-6.2; P = 0.005), gave the best fit under parsimony. Although the biological role of the I655V polymorphism is not known, large independent studies of early onset breast cancer are warranted to attempt to replicate this finding...
  16. pmc Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer
    Kylie L Gorringe
    Victorian Breast Cancer Research Consortium, Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Neoplasia 10:1253-8. 2008
    ..2% in ovarian cancer. Thus, CHD5 may play a role as a tumor suppressor gene in ovarian cancer; however, it is likely that there is another target of the frequent copy number neutral loss of heterozygosity observed at 1p36...
  17. ncbi request reprint BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer
    Kylie L Gorringe
    Peter MacCallum Cancer Centre, East Melbourne, Vic, 8006, Australia
    Breast Cancer Res Treat 111:505-9. 2008
    ....
  18. ncbi request reprint Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale
    Yoland C Antill
    Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Melbourne, Australia
    Cancer Epidemiol Biomarkers Prev 15:1396-8. 2006
    ..Interpretation of LOH is reliant on sufficient quality and quantity of DNA. We investigated LOH of the BRCA1/2 loci in DL samples from BRCA1/2 mutation carriers, while also assessing the effect of DNA quantity...
  19. ncbi request reprint Mutation analysis of EP300 in colon, breast and ovarian carcinomas
    Emma J Bryan
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Institute, Locked Bag No 1 A Beckett Street, East Melbourne, Victoria, Australia
    Int J Cancer 102:137-41. 2002
    ..Alternatively, silencing of EP300 may be achieved by epigenetic mechanisms such as promoter methylation...
  20. doi request reprint High-resolution copy number arrays in cancer and the problem of normal genome copy number variation
    Kylie L Gorringe
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Genes Chromosomes Cancer 47:933-8. 2008
    ....
  21. doi request reprint Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers
    Yoland C Antill
    Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer Epidemiol Biomarkers Prev 19:265-74. 2010
    ....
  22. ncbi request reprint Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas
    Maria I Patrikis
    Department of Obstetrics and Gynaecology, Gynaecological Cancer Research Centre, University of Melbourne, Royal Women s Hospital, Carlton, Victoria, Australia
    Mol Carcinog 37:61-4. 2003
    ..It is possible that CDP belongs to a class of tumor suppressor in which loss of only one copy of the gene, either by genetic or epigenetic mechanisms, is sufficient to allow tumor growth...
  23. ncbi request reprint Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus
    Wayne A Phillips
    Surgical Oncology Laboratory, Peter MacCallum Cancer Centre, and Department of Surgery St Vincent s Hospital, University of Melbourne, Parkville, Vic, Australia
    Int J Cancer 118:2644-6. 2006
    ....
  24. pmc No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas
    Wen Qiu
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    Nat Genet 40:650-5. 2008
    ..Our data show conclusively that LOH and copy number alterations are extremely rare in CAFs and cannot be the basis of the carcinoma-promoting phenotypes of breast and ovarian CAFs...
  25. ncbi request reprint Prohibitin 3' untranslated region polymorphism and breast cancer risk
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Cancer Epidemiol Biomarkers Prev 12:1273-4. 2003
  26. ncbi request reprint Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer
    Mira C P Liu
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Vic, Australia
    Cancer Lett 247:91-7. 2007
    ..Our data indicate that inactivation of TIMP-3 by somatic mutation or promoter hypermethylation is rare in ovarian cancer...
  27. pmc Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria, 3002, Australia
    Breast Cancer Res 4:R14. 2002
    ....
  28. ncbi request reprint Origin of carcinoma associated fibroblasts
    Izhak Haviv
    Baker IDI Institute, Prahran, Victoria, Australia
    Cell Cycle 8:589-95. 2009
    ..Here we review the definition of CAF phenotype and the evidence for each of those hypotheses, in the context of our current understanding of cancer etiology...
  29. doi request reprint Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis
    Kylie L Gorringe
    VBCRC Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Genes Chromosomes Cancer 48:931-42. 2009
    ..This study shows that recurrent regions of LOH and HD frequently align with known TSGs suggesting that LOH analysis remains a valid approach to discovering new candidates...
  30. ncbi request reprint High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications
    Kylie L Gorringe
    Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Clin Cancer Res 13:4731-9. 2007
    ..Genetic changes in sporadic ovarian cancer are relatively poorly characterized compared with other tumor types. We have evaluated the use of high-resolution whole genome arrays for the genetic profiling of epithelial ovarian cancer...
  31. ncbi request reprint Genetic analysis of benign ovarian tumors
    Nicola A Thomas
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Institute, East Melbourne, Australia
    Int J Cancer 105:499-505. 2003
    ..It does however provide a framework for future analysis of the molecular genetic etiology of ovarian tumorigenesis...
  32. doi request reprint Genetic analysis of cancer-implicated MicroRNA in ovarian cancer
    Jennifer L Bearfoot
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Clin Cancer Res 14:7246-50. 2008
    ..We investigated whether somatic mutations are a common mechanism of inactivation of microRNA genes in ovarian cancer...
  33. ncbi request reprint DNA microarrays for assessing ovarian cancer gene expression
    Izhak Haviv
    Signal Transduction Laboratory, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, VIC 3002, Australia
    Mol Cell Endocrinol 191:121-6. 2002
    ..In this review, we describe the technical aspects of DNA microarray analysis and some of the current and future applications of this technology for analysing gene expression in ovarian cancer...
  34. ncbi request reprint Whole genome SNP arrays using DNA derived from formalin-fixed, paraffin-embedded ovarian tumor tissue
    Ella R Thompson
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Hum Mutat 26:384-9. 2005
    ..This advance will open up vast archival tissue resources to high-resolution genetic analysis and unlock a wealth of biological information...
  35. ncbi request reprint A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition
    Briony E Cristiano
    Growth Control and Differentiation Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer Res 66:11718-25. 2006
    ..These findings are consistent with AKT3 playing a key role in the genesis of at least one subset of ovarian cancers...
  36. doi request reprint Large-scale genomic analysis of ovarian carcinomas
    Kylie L Gorringe
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Mol Oncol 3:157-64. 2009
    ..Future developments such as next-generation sequencing and integrated analysis of data from multiple array platforms on large numbers of samples are poised to revolutionize our understanding of this complex disease...
  37. ncbi request reprint Genome-wide, high-resolution detection of copy number, loss of heterozygosity, and genotypes from formalin-fixed, paraffin-embedded tumor tissue using microarrays
    Sharoni Jacobs
    Affymetrix, Inc, Santa Clara, California 95051, USA
    Cancer Res 67:2544-51. 2007
    ....
  38. ncbi request reprint Differential hypermethylation of SOCS genes in ovarian and breast carcinomas
    Kate D Sutherland
    The Walter and Eliza Hall Institute of Medical Research and Bone Marrow Research Laboratories, Royal Melbourne Hospital, Parkville, VIC 3050, Australia
    Oncogene 23:7726-33. 2004
    ..Hypermethylation and silencing of specific SOCS genes in the ovary, and to a lesser extent in breast, may augment cytokine responsiveness in these tissues, thereby contributing to oncogenesis...
  39. ncbi request reprint Mutational analysis of the LMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas
    Kate D Sutherland
    The Walter and Eliza Hall Institute of Medical Research and Bone Marrow Research Laboratories, Parkville, Australia
    Int J Cancer 107:155-8. 2003
    ..Thus, the primary mechanism by which LMO4 is deregulated in breast cancers appears to reflect overexpression of the gene rather than the acquisition of activating genetic mutations...
  40. ncbi request reprint PIK3CA mutations in ovarian cancer
    Ian G Campbell
    Clin Cancer Res 11:7042; author reply 7042-3. 2005
  41. ncbi request reprint Mutation and expression analysis of LZTS1 in ovarian cancer
    Jeremy M Arnold
    Queensland Institute of Medical Research, P O Box Royal Brisbane Hospital, Herston, QLD 4029, Australia
    Cancer Lett 233:151-7. 2006
    ..We have also analysed the coding region of the LZTS1 gene in 87 primary ovarian adenocarcinomas by DHPLC and detected a single silent somatic mutation. These data indicate that LZTS1 is not the target of LOH at 8p22 in ovarian cancer...
  42. ncbi request reprint EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer
    Jennifer L Clancy
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW 2010, Australia
    Oncogene 22:5070-81. 2003
    ..These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression...
  43. ncbi request reprint Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties
    James M Rae
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Clin Exp Metastasis 21:543-52. 2004
    ..Collectively, our results show that the MDA-MB-435 cells used widely have identical origins to those that exhibit a melanoma-like gene expression signature, but exhibit a small degree of genotypic and phenotypic drift...
  44. doi request reprint Breast-cancer stromal cells with TP53 mutations
    Ian G Campbell
    N Engl J Med 358:1634-5; author reply 1636. 2008
  45. ncbi request reprint Concentric left ventricular morphology in aerobically trained kayak canoeists
    Phillip E Gates
    Department of Exercise and Sport Science, The Manchester Metropolitan University, Alsager Faculty, Alsager ST7 2HL, UK
    J Sports Sci 22:859-65. 2004
    ..Thus aerobically upper body trained athletes demonstrated a concentric pattern of cardiac enlargement, but resting left ventricle function was not different between athletes, moderately active and sedentary individuals...
  46. ncbi request reprint Oncolysis of human ovarian cancers by echovirus type 1
    Darren R Shafren
    Picornaviral Research Unit, School of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Newcastle, Newcastle, New South Wales, Australia
    Int J Cancer 115:320-8. 2005
    ..These findings demonstrate an important proof of principle for employing wild-type EV1 as a potential oncolytic agent in the control of human ovarian cancers...
  47. ncbi request reprint LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines
    Erik W Thompson
    Invasion and Metastasis Unit, University of Melbourne, Department of Surgery, St Vincent s Hospital, 29 Regent St, Fitzroy, 3065, Australia
    Clin Exp Metastasis 21:535-41. 2004
    ..We also review the known misclassification of breast and prostate cancer cell lines to date and have initiated a register maintained at http://www.svi.edu.au/cell_lines_registry.doc...